Martina Pennisi - Concepedia

Author

Martina Pennisi

Fondazione IRCCS Istituto Nazionale dei Tumori ORCID

Also Known As

M Pennisi, M. Pennisi, Martina Pennisi, Matteo Pennisi

108

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori University of Milan Memorial Sloan Kettering Cancer Center Cornell University IRCCS Humanitas Research Hospital

About

Martina Pennisi is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	931
2	Health Sciences	3	3	71
3	Allergy	3	3	446
4	Blood Transplantation	3	3	76
5	Cell Biology	1	1	173

Martina Pennisi

Publications

Citations

H-Index

Page 1

	Year	Citations
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy Melody Smith, Anqi Dai, Guido Ghilardi, Nature Medicine DysbiosisAllergyGut Microbiome CorrelatesMucosal ImmunologyT-regulatory Cell	2022	285
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies Tania Jain, Andrea Knežević, Martina Pennisi, Blood Advances	2020	252
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma Kitsada Wudhikarn, M. Lia Palomba, Martina Pennisi, Blood Cancer Journal	2020	249
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells Martina Pennisi, Miriam Sánchez‐Escamilla, Jessica Flynn, Blood Advances T-regulatory CellImmune RegulationImmunologyEndothelial ActivationImmune System	2021	173
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management Martina Pennisi, Tania Jain, Bianca Santomasso, Blood Advances	2020	145
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality Kitsada Wudhikarn, Martina Pennisi, Marta García‐Recio, Blood Advances Clinical ImmunologyLow Nonrelapse MortalityImmunotoxicologyImmunodeficienciesImmunology	2020	135
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies David Sermer, Connie Lee Batlevi, M. Lia Palomba, Blood Advances Cell TherapyR/r DlbclImmunologyPathologyAlternate Therapies	2020	113
Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery Victoria Gutgarts, Tania Jain, Junting Zheng, Biology of Blood and Marrow Transplantation	2020	98
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas Peter A. Riedell, Wei‐Ting Hwang, Loretta J. Nastoupil, Transplantation and Cellular Therapy Hematological MalignancyLymphoid NeoplasiaOncologyResource UtilizationCommercial Axicabtagene Ciloleucel	2022	75
A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas Peter A. Riedell, Chase Walling, Loretta J. Nastoupil, Blood	2019	61

Page 1